| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 52.21 | -0.01 (-0.02%) | 41.68 - 52.65 | 1.4 million (Below Avg) |
Market data as of 4:00PM 05/20/13. Quotes are delayed by at least 15 min.
| Open | 52.19 |
|---|---|
| Previous Close | 52.22 |
| Day's Range | 52.08 - 52.46 |
| Market Cap | 128.6B |
| Avg Volume (10 Day) | 2.1M |
| Price/Earnings (Trailing 12 Mo.) | 19.5x |
| Earnings Per Share (Trailing 12 Mo.) | 2.68 |
| Dividend Yield | 0.55 (4.49%) |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Pass |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
BREO™ ELLIPTA™ gains US approval for the treatment of COPD
PR Newswire - Friday 05/10/2013 4:00 PM ET
| GSK | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -4.11% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 2.89 | |
| LT Debt/Equity | 2.58 | |
| Earnings Yield | 5.13% | |
| Price/Sales | 3.40 |
| Company | Last | Change |
|---|---|---|
| Merck & Co Inc | 45.21 | -1.70% |
| Sanofi SA | 53.84 | -1.21% |
| Novartis AG | 74.16 | +0.01% |
| Pfizer Inc | 28.70 | -0.90% |
| AbbVie Inc | 46.26 | -1.93% |
Data is delayed by at least 15 min.